Geode Capital Management LLC Purchases 2,877 Shares of Omnicell, Inc. (NASDAQ:OMCL)

Geode Capital Management LLC raised its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 0.3% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,104,745 shares of the company’s stock after buying an additional 2,877 shares during the period. Geode Capital Management LLC owned about 2.39% of Omnicell worth $48,176,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC grew its holdings in Omnicell by 248.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after buying an additional 1,000 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Omnicell by 78.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after purchasing an additional 553 shares during the last quarter. 1620 Investment Advisors Inc. boosted its stake in shares of Omnicell by 230.1% in the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after purchasing an additional 1,542 shares in the last quarter. Headlands Technologies LLC bought a new stake in shares of Omnicell during the second quarter worth $104,000. Finally, Summit Global Investments bought a new stake in Omnicell during the 3rd quarter worth $221,000. 97.70% of the stock is owned by institutional investors.

Omnicell Stock Performance

Shares of OMCL opened at $44.50 on Tuesday. Omnicell, Inc. has a fifty-two week low of $25.12 and a fifty-two week high of $55.74. The stock has a market cap of $2.06 billion, a PE ratio of -114.10, a price-to-earnings-growth ratio of 34.96 and a beta of 0.78. The firm’s 50-day simple moving average is $45.55 and its two-hundred day simple moving average is $39.55.

Analysts Set New Price Targets

Several brokerages recently weighed in on OMCL. Craig Hallum boosted their price objective on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Bank of America reiterated a “neutral” rating and issued a $57.00 price objective (up previously from $44.00) on shares of Omnicell in a research note on Thursday, October 31st. JPMorgan Chase & Co. increased their price objective on shares of Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research report on Thursday, November 21st. Barclays increased their price objective on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research note on Thursday, October 31st. Finally, Wells Fargo & Company boosted their price objective on Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research report on Monday, October 14th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, Omnicell has a consensus rating of “Hold” and a consensus target price of $52.00.

Insiders Place Their Bets

In related news, Director Mark W. Parrish sold 12,000 shares of the company’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the sale, the director now owns 58,427 shares in the company, valued at approximately $2,763,597.10. This represents a 17.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 2.64% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.